Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

902
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
902
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

611
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
611
Pulmonary Function Tests01:25

Pulmonary Function Tests

1.2K
Pulmonary Function Tests (PFTs)
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...
1.2K
Radiological Investigation III: Pulmonary Angiogram and PET Scan01:13

Radiological Investigation III: Pulmonary Angiogram and PET Scan

716
Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
716
Pulmonary Embolism I: Introduction01:29

Pulmonary Embolism I: Introduction

1.5K
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
1.5K
Other Pulmonary Disorders01:17

Other Pulmonary Disorders

1.8K
Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Is pregnancy feasible in women with adult granulosa cell tumors, and how should recurrence during pregnancy be managed? A case report and literature review.

Gynecologic oncology reports·2026
Same author

Streptozotocin plus 5-fluorouracil followed by everolimus or the reverse sequence in patients with advanced pancreatic neuroendocrine tumors (SEQTOR-GETNE phase III study): a randomized clinical trial.

ESMO open·2025
Same author

Optimization and evaluation of new decontamination procedures inactivating human prions.

The Journal of hospital infection·2025
Same author

Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET study.

Endocrine-related cancer·2024
Same author

MAST® D72C test: a novel option for ESBL, AmpC and carbapenemase detection.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2024
Same author

Could microbiological epidemiology guide the choice of antibiotic prophylaxis and implantation site for abdominal wall prostheses?

Journal of visceral surgery·2022

Related Experiment Video

Updated: Apr 27, 2026

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.7K

[Pulmonary neuroendocrine neoplasms].

Y Sayeg1, M Sayeg2, R P Baum3

  • 1Klinik für Pneumologie der Zentralklinik Bad Berka GmbH.

Pneumologie (Stuttgart, Germany)
|July 10, 2014
PubMed
Summary

Pulmonary neuroendocrine neoplasms (PNENs) are rare lung tumors with increasing incidence. Early diagnosis and a multidisciplinary approach are crucial for personalized treatment and improved survival rates in patients with these tumors.

More Related Videos

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
08:57

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

3.1K
Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
07:43

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

18.5K

Related Experiment Videos

Last Updated: Apr 27, 2026

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.7K
Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
08:57

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

3.1K
Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
07:43

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

18.5K

Area of Science:

  • Oncology
  • Pulmonology
  • Pathology

Context:

  • Pulmonary neuroendocrine neoplasms (PNENs) originate from enterochromaffin cells and represent 1-2% of all lung tumors.
  • Their incidence has risen due to improved diagnostics, necessitating updated classification and understanding.
  • PNENs encompass typical carcinoids (TC), atypical carcinoids (AC), large cell neuroendocrine carcinomas (LCNEC), and small cell lung cancer (SCLC).

Purpose:

  • To provide an overview of PNEN classification, biomarkers, clinical presentation, and treatment strategies.
  • To highlight the prognostic differences between various PNEN subtypes based on mitotic rate and Ki-67.
  • To emphasize the importance of a multidisciplinary approach for personalized patient management.

Summary:

  • PNENs are classified based on morphology and proliferation markers (mitotic rate, Ki-67), with TC and AC being less aggressive than LCNEC and SCLC.
  • Diagnostic biomarkers include chromogranin A, synaptophysin, and CD56.
  • Treatment options range from surgical resection and endoscopic procedures to peptide receptor radionuclide therapy (PRRT) and emerging targeted therapies.

Impact:

  • Accurate classification and understanding of PNENs guide treatment decisions and prognostic assessments.
  • Multidisciplinary tumor conferences are essential for optimizing personalized treatment plans.
  • Specialized centers are recommended for managing patients with neuroendocrine neoplasms of the lung to ensure optimal outcomes.